<DOC>
	<DOCNO>NCT01076439</DOCNO>
	<brief_summary>The purpose study evaluate onset action fluticasone furoate nasal spray compare olopatadine nasal spray placebo nasal spray reduce nasal allergic sign symptom follow ragweed exposure Allergen BioCube ( ABC ) single dose administration six consecutive day treatment .</brief_summary>
	<brief_title>An Allergen BioCube ( ABC ) Study Evaluating Onset Action Fluticasone Furoate Nasal Spray Olopatadine Nasal Spray Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<criteria>provide write informed consent sign HIPAA form ; able willing follow instruction attend study visit ; female childbearing potential , pregnant , nurse planning pregnancy , willing submit pregnancy test visit 1 exit visit , use adequate method birth control positive history seasonal allergic rhinitis ragweed ; positive skin test reaction ragweed within past 24 month ; manifest sufficient allergic rhinitis symptom ragweed exposure ABC manifest symptom clinically active allergic rhinitis start Visit 1 Visit 2 ; know intolerance allergy antihistamine corticosteroid ; compromise lung function Visit 1 ; significant nasal anatomical deformity condition allow subject breathe nose ( include , limited : septal deviation , septal perforation , nasal polyp , rhinitis medicamentosa ) nasal surgical intervention past ; plan surgery ( nasal , ocular systemic ) trial period within 30 day thereafter ; use disallow medication ( topical , topical ophthalmic , systemic and/or injectable treatment antiallergy therapy include prescription , counter homeopathy , counter sleep aid ) study appropriate prestudy washout period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>